Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent
Good health with the exception of bronchial asthma (for at least 6 months)
FEV1 \> 60% to \< 80% of predicted (if pretreated with inhaled steroids only)
FEV1 \> 60% to ≤ 85% of predicted (if pretreated with inhaled steroids in combination with other asthma controller)
You may not be if
Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids or long-acting beta2-agonists
Chronic obstructive pulmonary disease (COPD), i.e. chronic bronchitis or emphysema, and/or other relevant lung diseases causing alternating impairment in pulmonary function
Current smoking or cessation of smoking within the last 6 months or previous smoking with a smoking history ≥ 10 cigarette pack-years
Use of other drugs not allowed
Pregnancy or intention to become pregnant during the course of the study, breast feeding, or lack of safe contraception in women of childbearing potential
Clareo Health | Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)
